Vasopressin and its antagonists: What are their roles in acute medical care?

British Journal of Anaesthesia

Volumn 99, Issue 2, 2007, Pages 154-158

  Mitchell, S L M ^a   Hunter, J M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CATECHOLAMINE; CLARITHROMYCIN; CONIVAPTAN; DIURETIC AGENT; DOBUTAMINE; HETASTARCH; HYDROCORTISONE; LEVOTHYROXINE; LIOTHYRONINE; LIXIVAPTAN; METHYLPREDNISOLONE; MILRINONE; NORADRENALIN; PLACEBO; RINGER LACTATE SOLUTION; SIMVASTATIN; STEROID; TERLIPRESSIN; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR;

ANESTHESIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY; DEHYDRATION; DIABETES INSIPIDUS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; EMERGENCY CARE; FLUID BALANCE; HEART ARREST; HEART MUSCLE ISCHEMIA; HEMORRHAGIC SHOCK; HORMONE ACTION; HUMAN; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY POLYCYSTIC DISEASE; LOW DRUG DOSE; NEUROENDOCRINE TUMOR; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SYNCOPE; THIRST; VASOCONSTRICTION; XEROSTOMIA;

EID: 34547881087     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aem204     Document Type: Editorial

References (32)

1. Dunser MW, Lindner KH, Wenzel V. A century of arginine vasopressin research leading to new therapeutic strategies. Anesthesiology 2006; 105: 444-5
2. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004; 30; 1276-91
3. Kinoshita Y, Yahata K, Yoshioka T, Onishi S, Sugimoto T. Long-term renal preservation after brain death maintained with vasopressin and epinephrine. Transpl Int 1990; 3: 15-8
4. Rosendale JD, Kauffman HM, McBride MA. et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003; 75: 482-7
5. Lindner KH, Haak T, Keller A, Bothner U, Lurie KG. Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart 1996; 75: 145-50
6. Wyer PC, Perera P, Jin Z, et al. Vasopressin or epinephrine for out-of-hospital cardiac arrest. Ann Emerg Med 2006; 48: 86-97
7. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112: IV1-203
8. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-5
9. Leone M, Boyle WA, Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Crit Care Med 2006; 34: 1126-30
10. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32: 858-73
11. Sprung CL, Annane D, Briegel J, et al. Corticosteroid therapy of septic shock. Am J Resp Crit Care Med 2007; 175: A507 (Abstract issue)
12. Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock: Systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003; 95: 803-9
13. Levy B, Vallee C, Lauzier F, et al. Comparative effects of vasopressin, norepinephrine, and L-canavanine, a selective inhibitor of inducible nitric oxide synthase, in endotoxic shock. Am J Physiol Heart Circ Physiol 2004; 287: H209-215
14. Dellinger RP, Carlet JM, Masur H. et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-55
15. Russell JA, Walley KR, Singer J, et al. A randomised controlled trial of low dose vasopressin versus norepinephrine infusion in patients who have septic shock. Am J Resp Crit Care Med 2007; 175: A508 (Abstract issue)
16. Walley KR, Gordon AC, Russell JA. Hemodynamic effects of vasopressin versus norepinephrine in septic shock in the VASST cohort. Am J Resp Crit Care Med 2007; 175: A594 (Abstract issue)
17. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: Vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006; 40: 2170-7
18. Raedler C, Voelckel WG, Wenzel V, et al. Treatment of uncontrolled hemorrhagic shock after liver trauma: Fatal effects of fluid resuscitation versus improved outcome after vasopressin. Anesth Analg 2004; 98: 1759-66
19. Krismer AC, Wenzel V, Voelckel WG, et al. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock. Three cases and a brief analysis of the literature. Anaesthesist 2005; 54: 220-4
20. Augoustides JG, Abrams M, Berkowitz D, Fraker D. Vasopressin for hemodynamic rescue in catecholamine-resistant vasoplegic shock after resection of massive pheochromocytoma. Anesthesiology 2004; 101 1022-4
21. Rossi J, Orlandi C, Gheorghiade M. Vasopressin antagonists in the management of heart failure. Expert Rev Cardiovasc Ther 2007; 5 323-30
22. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69: 2124-30
23. De Luca L, Orlandi C, Udelson JE, Fedele F, Gheorghiade M. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. Am J Cardiol 2005; 96: 24-33L
24. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297: 1319-31
25. Gheorghiade M, Konstam, MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan an oral vasopressin antagonist in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-43
26. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan a dual V(1A) V(2) vasopressin receptor antagonist in patients with advanced heart failure. Circulation 2001; 104: 2417-23
27. Londono MC, Guevara M. Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130: 1135-43
28. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355: 2099-112
29. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986; 314 1535-42
30. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: A prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985; 102: 164-8
31. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: A VIA/V2 vasopressin receptor antagonist assessed in a randomized placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91: 2145-52
32. Treschan TA, Peters J. The vasopressin system: Physiology and clinical strategies. Anesthesiology 2006, 105: 599-612